Johnson & Johnson announced that the FDA has approved TREMFYA, or guselkumab, the first and only IL-23 inhibitor ...

Tremfya (guselkumab) is a brand-name drug approved to treat ulcerative colitis (UC). This article covers topics such as side effects, dosage, and how Tremfya works. Tremfya is available as a ...

Johnson and Johnson’s (J&J) fully subcutaneous Tremfya (guselkumab) has shown a second round of success in ulcerative colitis (UC), with 27.6% of patients achieving clinical remission in a Phase ...

Johnson & Johnson has filed its IL-23 inhibitor Tremfya for approval in psoriatic arthritis (PsA), its second indication, setting up what could be another brutal battle for market share.

NICE has updated its recommendations for NHS use of Johnson & Johnson's IL-23 inhibitor Tremfya in the treatment of psoriatic arthritis (PsA), expanding the pool of patients eligible for treatment ...

Read the Medication Guide and Instructions for Use provided by your pharmacist before you start using this medication and each time you get a refill. Ask your health care professional how to ...

Johnson & Johnson (J&J) has shared positive results from a late-stage study evaluating a subcutaneous (SC) version of Tremfya (guselkumab) in ulcerative colitis (UC). The phase 3 ASTRO trial has been ...